Genetron Health to Join Science Webinar with Johns Hopkins University on Liquid Biopsy and the Future of Early Cancer Detection

Genetron Holdings Limited (NASDAQ: GTH) announced yesterday that it will participate in an online seminar on early cancer screening hosted by the world-renowned academic journal Science on March 31. As a global leader in precision oncology, Genetron will feature Dr. Yuchen Jiao, Chief Technology Officer, in an authoritative discussion with Dr. Anne Marie Lennon, Director of the Division of Gastroenterology and Hepatology at Johns Hopkins University. The dialogue will center on the theme “The Present and Future of Early Cancer Screening: Exploring Liquid Biopsy Analytics for Diagnosis and Treatment.”

Cancer early screening was frequently mentioned during this year’s Two Sessions, becoming a hot topic of public interest. What role does cancer early screening play in the full-cycle management of cancer? What are the cutting-edge screening technologies and methods? What is the clinical application outlook? At this seminar, two authoritative experts from China and the United States will discuss these topics.

Online registration for this symposium is now open (click the link below to register). Colleagues worldwide are welcome to tune in online.https://www.sciencemag.org/custom-publishing/webinars/early-cancer-screening-today-and-tomorrow-exploring-liquid-biopsy

Genetron Holdings (NASDAQ: GTH) is a global leader in precision oncology, dedicated to advancing cancer genomics research and applications. The company is committed to transforming cancer diagnosis and treatment by leveraging advanced molecular biology and big data analytics. Genetron has established a comprehensive portfolio of products and services spanning the entire cancer care continuum—from early screening, diagnosis, and treatment recommendations to monitoring and prognosis management. Furthermore, the company actively collaborates with partners across the industry value chain to expand innovative applications and scenarios for molecular testing technologies.